NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT1041240078

Registered date:29/08/2024

SAVANT study

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedHypertension caused by Angiogenesis Inhibitor
Date of first enrollment29/08/2024
Target sample size40
Countries of recruitment
Study typeInterventional
Intervention(s)Patient with hypertension due to angiogenesis inhibitor is treated with combination therapy of sacubitril/valsartan200mg and amlodipine5mg. Changes of blood pressure are monitored for 3 weeks (+- 1 week) after the start of treatment.

Outcome(s)

Primary OutcomeRate of blood pressure control
Secondary OutcomeAdverse events Change of blood-pressure value

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximumNot applicable
GenderBoth
Include criteria(1) Pathologically diagnosed with cancer (2) Diagnosed with drug-induced hypertension caused by angiogenesis inhibitors (3) One calcium antagonist or ARB/ACE inhibitor is used (4) Angiogenesis inhibitor is continued. (5) Creatinine is less than 1.5 mg/dL (6) 18 years or older (7) Written informed consent was obtained
Exclude criteria(1)Severe hypertention (CTCAEv5, Grade4) (2)Essential hypertension (Blood pressure 140/90mmHg or more before starting treatment with angiogenesis inhibitors) (3)History of secondary hypertension

Related Information

Contact

Public contact
Name Takuya Oyakawa
Address 1007Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka Shizuoka Japan 411-8777
Telephone +81-55-989-5222
E-mail t.oyakawa@scchr.jp
Affiliation Shizuoka Cancer Center
Scientific contact
Name Nao Muraoka
Address 1007Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka Shizuoka Japan 411-8777
Telephone +81-55-989-5222
E-mail n.mochizuki@scchr.jp
Affiliation Shizuoka Cancer Center